Adjuvant Nivolumab or Ipilimumab plus Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

Journal article

Peer reviewed

Tahsin M. Khan, Martha E. Teke, Giorgos C. Karakousis, John T. Miura, Robert M. Brody, Jonathan M. Hernandez and Tara C. Mitchell

Annals of surgical oncology, Vol.29(5), pp.2771-2772

05/01/2022

DOI: 10.1245/s10434-021-11199-0

PMID: 35061122

View Online

no abstract

Oncology

Surgery

Life Sciences & Biomedicine

Science & Technology

Title: Subtitle: Adjuvant Nivolumab or Ipilimumab plus Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
Creators: Tahsin M. Khan - National Institutes of Health
Martha E. Teke - National Institutes of Health
Giorgos C. Karakousis - University of Pennsylvania
John T. Miura - University of Pennsylvania
Robert M. Brody - University of Pennsylvania
Jonathan M. Hernandez - National Institutes of Health
Tara C. Mitchell - University of Pennsylvania
Resource Type: Journal article
Publication Details: Annals of surgical oncology, Vol.29(5), pp.2771-2772
DOI: 10.1245/s10434-021-11199-0
PMID: 35061122
NLM abbreviation: Ann Surg Oncol
ISSN: 1068-9265
eISSN: 1534-4681
Publisher: Springer Nature
Number of pages: 2
Grant note: ZIABC011861 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Language: English
Date published: 05/01/2022
Academic Unit: Surgery
Record Identifier: 9985224319402771

2 Record Views